Zenas Bio inflammation drug meets Phase 3 goals

Zenas Biopharma's obexelimab achieved a statistically significant and clinically meaningful reduction in signs and symptoms of immunoglobulin G4-related disease, but not to the extent shown by Amgen's Uplizna in its pivotal study. Still, Zenas points to features of its drug that could make it competitive as a maintenance therapy for the rare autoimmune disorder.

Editor's Pick

Top Story Zenas Bio Inflammation Drug Meets Phase 3 Goals, But Is It Enough to Compete With Amgen? Zenas Biopharma's obexelimab achieved a statistically significant and clinically meaningful reduction in signs and symptoms of immunoglobulin G4-related disease, but not to the extent shown by Amgen's Uplizna in its pivotal study. Still, Zenas points to features of its drug that could make it competitive as a maintenance therapy for the rare autoimmune disorder. Sponsored How UberDoc is Carving a Niche in Healthcare Presented by UberDoc CEO Sean Kearney talked about its approach, plans for 2026 and how companies like UberDoc make healthcare cheaper.  To simplify booking appointments with primary and specialty care physicians through a platform where patients or self-funded employers pay out of pocket for their care.  Learn More

Featured News

AMA to Congress: Make Medicare Telehealth Services Permanent The American Medical Association is urging Congress to permanently extend Medicare's pandemic-era telehealth flexibilities, warning that temporary extensions create uncertainty for patients and providers. The Healthcare Sector's Digital Contagion: Ransomware's Relentless Grip In a sector where delays are measured in lives, early detection, lower attacker dwell time, and system-level misdirection can literally save lives. By marrying preemptive and deceptive technologies, organizations can blunt the attack surface while simultaneously exposing hidden threats before damage is done.  2026 Healthcare Outlook: A Year of Unprecedented Disruption There is no question the pressures are heavy, but there is also an opportunity for organizations to rethink how they deliver care, how they support the people they serve, and how they invest limited resources. The Front Door of Healthcare Isn't What You Think: How the Patient Payment Experience Defines Loyalty When paying for care becomes a source of frustration, patients feel the pain. When the process feels easier elsewhere, they're more likely to look for a new provider. Getting these processes right isn't just about convenience, it's about preserving trust and strengthening long-term relationships with patients.

Video   How Oura is moving beyond wellness Oura is no longer just a sleep-focused wellness startup. It's getting deeper into chronic disease management and healthcare integration, said its chief medical officer, Ricky Bloomfield.

Sponsored How and Where to Apply for a Covered California Health Insurance Plan Presented by Health for California The marketplace allows you to compare standardized plans, access subsidies and enroll with confidence. Using a certified enrollment partner, such as Health for California, ensures that your application is accurate, supported and submitted through an authorized channel. Learn More

Resources

MedCity FemFwd: The Importance of Virtual Maternal-Fetal Medicine In this episode, we're joined by Dr. Blake Porter, chief of maternal-fetal medicine with Access TeleCare. He discusses the need to expand access to virtual maternal-fetal medicine care. View Now

MedCity News • PO Box 901 • New York, NY unsubscribe